Germfree expands its Board of Directors with the addition of four members

Germfree has announced the addition of Dorothy Puhy, Karen Flynn, Kerry Ingalls and Helga Salling as independent non-executive members of its Board of Directors. Germfree CEO Kevin Kyle highlights the importance of this addition in guiding the company towards sustainable growth and long-term success, leveraging their collective expertise to navigate future challenges and exploit opportunities, particularly in emerging areas of cell and gene therapy.

Dorothy Puhy brings notable financial experience, having held leadership positions at Dana Farber Cancer Institute and Abiomed. Karen Flynn has over thirty years of commercial and operations experience, most recently with Catalent. Kerry Ingalls, former COO of Poseida Therapeutics, brings expertise in pharmaceutical manufacturing and operations, while Helga Salling, current VP at Jacobs, strengthens the board with more than 20 years of experience in life sciences.

The four new members are expected to bring fresh dynamics and strategic leadership to Germfree, supporting its ambition to effectively meet market needs in the cell and gene therapy sector, according to Evis Hursever, Managing Director at EW Healthcare Partners and Chairman from the administration board.